Sebastián Felipe Sierra-Umaña

Sebastián Felipe Sierra-Umaña

Auto-generated profile, based on publicly available information

Sebastián Felipe Sierra-Umaña

Subred Integrada de Servicios de Salud Sur E.S.E. Hospital Tunal, Bogotá 110621, Colombia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2023 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
COCynthia Ortiz-Roa
Cynthia Ortiz-Roa
MRMartha Carolina Valderrama Rios
Martha Carolina Valderrama Rios
SSSebastián Felipe Sierra-Umaña
Sebastián Felipe Sierra-Umaña
JJose Yesid Rodriguez
Jose Yesid Rodriguez
GMGerardo Antonio Muñetón-López
Gerardo Antonio Muñetón-López
JCJorge Alberto Cortes
Jorge Alberto Cortes
Candida auris is an emerging pathogen considered to be critical in the World Health Organization fungal organisms list. The study aims to determine the mortality and hospital stays attributed to Candida auris (C. auris) compared to other Candida species in adult patients with candidemia. A retrospective cohort of adults with candidemia was examined from seven centres in Colombia between 2016 and 2021. The primary outcome was 30-day mortality, and the secondary outcome was the length of hospital stay among survivors. Adjustment of the confounding variables was performed using inverse probability weights of exposure propensity score (candidemia by C. auris), survival regression models (Weibull distribution), and a counting model (negative binomial distribution). A value of 244 (47.6%) of the 512 patients with candidemia died within the first 30 days. The crude mortality in C. auris was 38.1% vs. 51.1% in Candida non-auris (CNA). In the Weibull model, mortality in the C. auris group was lower (adjusted HR: aHR- 0.69, 95% CI: 0.53–0.90). Antifungal treatment also decreased mortality, with an aHR of 0.36 (95% CI 0.27–0.47), while the presence of septic shock on patient progression increased it, with an aHR of 1.73 (95% CI 1.41–2.13). Among the patients who survived, no differences in the length of hospital stay were observed between the C. auris and the CNA groups, with an incidence rate ratio of 0.92 (95% CI: 0.68–1.22). Mortality in patients with C. auris bloodstream infections appears lower when adjusted for numerous confounding variables regarding treatment and the presence of septic shock in patient progression. We identified no significant effect of C. auris on the length of hospital stay in surviving patients.

12 October 2022 in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
Verified
Journal Article
Open access
PDF file
SUSebastian Felipe Sierra Umaña
Sebastian Felipe Sierra Umaña
AAAndrés Garcés Arias
Andrés Garcés Arias
SMSebastian Salinas Mendoza
Sebastian Salinas Mendoza
CRCristian Alejandro Castillo Rodríguez
Cristian Alejandro Castillo Rodríguez
JGJuan Pablo Alzate Granados
Juan Pablo Alzate Granados
Contexto: Factores dietarios poco saludables se han asociado con aumento de riesgo cardiovascular, uno de ellos; consumo de azúcar. Objetivo: Búsqueda, evaluación y análisis de la mejor evidencia disponible sobre el consumo de azúcar y desenlaces mayores cardiovasculares. Metodología: Revisión sistemática de la literatura. Evaluación cuantitativa entre consumo de azúcar y alguno de los siguientes eventos cardiovasculares mayores (muerte cardiovascular, infarto agudo de miocardio no fatal o accidente cerebrovascular no fatal). Se incluyeron participantes mayores de 18 años no gestantes, sin cardiopatía congénita. Resultados: Se incluyeron 31 estudios primarios (27 estudios de cohortes y 4 estudios de casos y controles). Veintiuno evaluaron el consumo de azúcar e infarto agudo de miocardio, 12 consumo de azúcar y accidente cerebrovascular y 6 consumo de azúcar y muerte cardiovascular. Para los 3 desenlaces los resultados fueron controversiales, sin embargo, con significancia estadística en varios estudios para la asociación en cuestión, al evaluarse el consumo de azúcar por carga glucémica, índice glucémico, carbohidratos totales, entre otros. Conclusiones: Sin bien la evidencia es contradictoria, sugiere de forma consistente a partir de estudios de cohorte que los carbohidratos con alto índice glucémico, azucares añadidos y bebidas azucaradas, aumentan el riesgo de presentar eventos adversos cardiovasculares mayores como infarto agudo de miocardio, ataque cerebrovascular y muerte cardiovascular.

1 July 2019 in Case reports
Verified
Journal Article
Open access
PDF file
LFLaura Marcela Fino-Velásquez
Laura Marcela Fino-Velásquez
FZFernán Santiago Zambrano-Muñoz
Fernán Santiago Zambrano-Muñoz
AVAlejandro Vega-Molina
Alejandro Vega-Molina
SSSebastián Felipe Sierra-Umaña
Sebastián Felipe Sierra-Umaña
SRSilvio Javier Rosero-Paredes
Silvio Javier Rosero-Paredes
CDCamilo Alejandro Díaz-Rojas
Camilo Alejandro Díaz-Rojas
Introduction: Histoplasmosis is an opportu­nistic granulomatous fungal infection. Peritoneal histoplasmosis (PH) is a rare form of dissem­inated histoplasmosis (DH).Case description: A 44-year-old male pa­tient with history of HIV infection, systemic lupus erythematosus with lupus nephritis, and chronic kidney disease on peritoneal dialysis, presented with recurrent ascites without clear etiology in the serial study of ascitic fluid. Con­trast computed tomography of the abdomen showed a nonspecific peritoneal nodule, for which laparoscopy and biopsy were performed, identifying Histoplasma capsulatum infection. The subject received 15 days of in-hospital treatment with amphotericin B deoxycholate with good evolution, no recurrence of ascites, and indefinite outpatient management with itraconazole.Discussion: The first case of PH was described in 1970 but this is the first case reported in Co­lombia. Most cases of PH have been associated with peritoneal dialysis. Its diagnosis is based on the study of ascitic fluid and its treatment follows the guidelines of other forms DH.Conclusions: PH is a rare entity that requires high clinical suspicion, especially in immuno­compromised patients.

1 January 2017 in Case reports
Verified
Journal Article
Open access
PDF file
LMLaura Marcela
Laura Marcela
VGVelásquez Gaviria
Velásquez Gaviria
AAAndrés Garcés Arias
Andrés Garcés Arias
SFSebastián Felipe
Sebastián Felipe
SUSierra Umaña
Sierra Umaña
SMSalinas Mendoza
Salinas Mendoza
Introducción: el infarto pulmonar ocurre entre un 29 y un 32% de pacientes con tromboembolismo pulmonar (TEP). Por su parte, la infección de un infarto pulmonar complica aproximadamente del 2 al 7% de los casos, lo que hace que el infarto pulmonar infectado sea una entidad poco frecuente.Descripción del caso: mujer de 49 años con dolor pleurítico en hemitórax izquierdo, irradiado a región dorsal, asociado a disnea y edema doloroso de miembro inferior izquierdo de dos días de evolución. Dos semanas antes de su ingreso la paciente sufrió trauma de rodilla izquierda, el cual que requirió intervención quirúrgica; sin embargo, por motivos desconocidos, no recibió profilaxis anti trombótica. En el examen físico se encontró taquicardia, taquipnea y edema doloroso con eritema en pierna izquierda. Al existir alta sospecha de tromboembolia pulmonar se inició anticoagulación y se solicitó angiotomografía de tórax, con la cual fue posible confirmar el diagnóstico. Durante su evolución, la paciente experimentó signos de respuesta inflamatoria sistémica, deterioro respiratorio. Se realizó tomografía de control sugestiva de infarto pulmonar infectado. Se inició antibiótico y la paciente mejoró de forma progresiva; después de esta mejora, fue dada de alta para continuar anticoagulación y seguimiento ambulatorios.Conclusiones: el infarto pulmonar es una complicación frecuente en pacientes con TEP. Por lo tanto, debe sospecharse infarto pulmonar infectado en pacientes con deterioro clínico y respuesta inflamatoria sistémica. La diferencia radiológica entre infarto pulmonar y neumonía no es fácil de identificar, su enfoque diagnóstico es clínico y el tratamiento anticoagulante y antimicrobiano debe iniciarse de manera oportuna.

7 August 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
Mariana Pimiento DiazMariana Pimiento Diaz
Mariana Pimiento Diaz
COCynthia Ortiz-Roa
Cynthia Ortiz-Roa
SSSebastián Felipe Sierra-Umaña
Sebastián Felipe Sierra-Umaña
JRJosé Yesid Rodríguez
José Yesid Rodríguez
GMGerardo Antonio Muñetón-López
Gerardo Antonio Muñetón-López
JCJorge Alberto Cortes
Jorge Alberto Cortes
Background: Candidozyma auris (Candida auris) is an emerging multidrug-resistant fungal pathogen that can cause hospital outbreaks and is associated with high mortality. However, data on the clinical predictors of mortality in patients with bloodstream infection (BSI) caused by C. auris remain limited, particularly in Latin America, and the impact of guideline-based management practices on clinical outcomes has been scarcely explored. Methods: We conducted a multicenter retrospective cohort study including 134 patients with culture-proven C. auris BSI admitted to seven hospitals in Colombia between 2016 and 2021. Demographic, clinical, and therapeutic variables were evaluated to identify factors associated with 30-day mortality using a multivariate logistic regression model. Variables related to quality of care and guideline-based candidemia management, included in the EQUAL Candida Score, were also assessed. Results: The thirty-day mortality rate was 38.1%. In the multivariate analysis, older age (OR per decade: 1.37; 95% CI: 1.07–1.78), prior corticosteroid therapy (OR: 4.06; 95% CI: 1.70–10.16), and shock within 48 h of BSI (OR: 6.22; 95% CI: 2.52–16.52) were associated with higher mortality. Conversely, a higher EQUAL Candida Score was associated with lower 30-day mortality (OR: 0.84; 95% CI: 0.73–0.97). Conclusions: In this large Colombian cohort, advanced age, corticosteroid exposure, and early hemodynamic instability were significant predictors of mortality in patients with C. auris BSI. Greater adherence to recommended management practices—as reflected by the EQUAL Candida Score—appeared to be associated with lower mortality, underscoring the potential role of timely, structured care strategies in improving outcomes for patients with C. auris infections. To the best of our knowledge, this study is the first to evaluate the EQUAL Candida Score in a cohort of patients with C. auris BSI.

1 July 2019 in Case reports
Verified
Journal Article
Open access
PDF file
SSSebastián Felipe Sierra-Umaña
Sebastián Felipe Sierra-Umaña
RGRafael García-Sanchez
Rafael García-Sanchez
LULaura Camila Urrutia-Corredor
Laura Camila Urrutia-Corredor
JOJessica Tatiana Olarte-Luis
Jessica Tatiana Olarte-Luis
DCDolli Yineth Cáceres-Galíndez
Dolli Yineth Cáceres-Galíndez
Introduction: Congenital fibrinogen disorders are rare conditions in which there are quantitative and qualitative alterations of factor I; the vast majority of patients are asymptomatic.Case presentation: A 19-year-old female patient with a history of congenital hypofibrinogenemia presented with spontaneous vulvar hematoma along with hypotension, tachycardia, stupor and hematoma of 20cm in the right labium majus. On admission, the young woman had hemoglobin 6.6 g/dL, fibrinogen 74 mg/dL and prolonged clotting times. She received red blood cells transfusion and cryoprecipitates, followed by surgical drainage and intravenous fibrinogen replacement, adjusting the dose according to fibrinogen levels in plasma. The patient presented progressive improvement without hemorrhagic recurrence and fibrinogen levels within the target values until hospital discharge.Discussion: Afibrinogenemia and hypofibrin­ogenemia are part of the quantitative factor I disorders; in the first case, there is total absence of circulating fibrinogen, and in the second case the levels are below 150 mg/dL. Sponta­neous vulvar hematoma as a severe hemorrhagic manifestation is not frequent in symptomatic patients; its treatment is based on fibrinogen replacement in an individualized manner and surgical management when required.Conclusion: Hypofibrinogenemia is a rare dis­ease, and fibrinogen replacement is one of the mainstays of treatment.